Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. - Gale, D.; Heider, K.; Ruiz-Valdepenas, A.; Hackinger, S.; Perry, M.; Marsico, G.; Rundell, V.; Wulff, J.; Sharma, G.; Knock, H.; Castedo, J.; Cooper, W.; et al. (Annals of Oncology, 2022)